Search for Stocks /

Procter & Gamble Health Ltd Q1FY26 – “Vitamin Profits, Supplemented by Royalties: 36% ROE Served with 2% Dividend”

Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.

1. At a Glance

P&G Health (PGHL) – the Indian arm of the global FMCG–pharma monster – closed at ₹6,288 with a market cap of ₹10,433 Cr. FY25 sales were ₹1,273 Cr, with a juicy PAT of ₹301 Cr, giving it a P/E of ~35x. Dividend yield sits near 2%, and the company flaunts an ROE of 36% and ROCE of 48%. Compare this to the cement jokers we roasted last week – this one’s basically printing vitamins and dividends. In the last 6 months, the stock returned 22%, in 1 year 20%. Clearly, health is wealth… unless you’re paying 19x book value for it.


2. Introduction

P&G Health is like that one rich cousin who casually flexes – “I just do vitamins, bro” – and yet drives a BMW. Originally Merck Ltd, it was swallowed by P&G in 2018 as part of a $4.2B global deal. Since then, PGHL has become India’s biggest VMS (Vitamins, Minerals, Supplements) player.

Its products are less “pharma life-saving” and more “middle-class auntie swears by this” – Evion, Neurobion, Livogen, Nasivion, Seven Seas. Chances are your mom has at least one in her medicine cabinet.

This isn’t a mass generic play like Cipla or Dr Reddy’s. It’s premium OTC, high-margin, brand-led pharma. The Goa factory isn’t churning out injections anymore (outsourced since FY24) – instead, it makes sure you pop shiny supplements while sending royalties (₹24 Cr FY23) to Uncle P&G in the US.

Reader check: How do you feel about paying Wall Street royalties every time you swallow a Neurobion?


3. Business Model – WTF Do They Even Do?

The company is a pure-play branded pharma–consumer health business:

  • Products: Evion (Vitamin E), Livogen (Iron), Neurobion (B-vitamins), Seven Seas (cod liver oil), Nasivion (nasal spray), Polybion (tonics). Basically, “health insurance in strip form.”
  • Revenue Split: 90% from India, 10% exports. Don’t expect global dominance – it’s very much a “Bharat vitamin business.”
  • Distribution: Transitioned in FY23 from carrying & forwarding agents to direct distributor-led model. Also ramping up omnichannel presence (online + offline pharmacies).
  • CSR/Marketing Disguised as Campaigns: Runs bus yatras for anemia awareness, and diabetes day campaigns – nice way to market without calling it marketing.

In short: PGHL is a

Read Full 16 Point breakdown. Continue reading →
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →